Dexpanthenol

Summary

Dexpanthenol (CHEMBL1200979) is an approved small-molecule cholinergic drug (ATC D03AX03); indicated across 6 conditions including eye disorder and skin disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: D03AX03 (+2 more)
• Indications: 6 conditions
• Clinical trials: 8
• Chemistry: 205.25 Da · C9H19NO4

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL1200979
Name	Dexpanthenol
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	131204
ChEBI	CHEBI:27373
ATC	D03AX03, A11HA30, S01XA12
Molecular formula	C9H19NO4
Molecular weight	205.25
InChIKey	SNPLKNRPJHDVJA-ZETCQYMHSA-N

SMILES: CC(C)(CO)[C@H](C(=O)NCCCO)O

IUPAC name: (2R)-2,4-dihydroxy-N-(3-hydroxypropyl)-3,3-dimethylbutanamide

ChEBI definition: A monocarboxylic acid amide that is 3,3-dimethylbutanamide substituted by hydroxy groups at positions 2 and 4 and a 3-hydroxypropyl group at the carbomyl nitrogen.

Pharmacological roles (ChEBI): cholinergic drug, provitamin.

Also known as: (+)-panthenol, D-panthenol, D-pantothenyl alcohol, Dexpantenol, Dexpanthenol, Ilopan, Pantothenol, DEXPANTHENOL, SID170464647, (D)-Panthenol, dexpanthenol

Patent coverage: 7,325 distinct patent families (19,010 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 2 (assay-derived). Sample: Prostaglandin G/H synthase 1, Voltage-gated inwardly rectifying potassium channel KCNH2.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

1 approved indication. FDA phase 4, plus an anticancer drug’s labelled cancer uses (which ChEMBL often logs at phase 3).

Indication	Phase	MONDO	EFO
eye disorder	4	MONDO:0005328	EFO:0003966

3 diseases in clinical trials (phase 1–3, investigational — not approved indications). Highest ChEMBL trial phase per disease; a non-cancer approved use is occasionally logged at phase 3 here.

Disease (in trials)	Phase	MONDO	EFO
skin disorder	3	MONDO:0005093	EFO:0000701
stomatitis	2	MONDO:0004842	EFO:1001904
cheilitis	1	MONDO:0002102	MONDO:0002102

2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 8.

Phase distribution

Phase	Trials
PHASE4	2
PHASE3	2
Not specified	2
PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06822608	PHASE4	NOT_YET_RECRUITING	Evaluation of Dexpanthenol and Hyaluronic Acid Eye Drops on Corneal Epithelialization After Trans Epithelial PRK
NCT00859196	PHASE4	COMPLETED	Study to Assess on a Molecular Level the Influence of a 5 % Dexpanthenol Ointment in Subjects With Superficial Injuries
NCT00661102	PHASE3	COMPLETED	A Study of Prophylactic Treatment for Hand-Foot Syndrome in Patients Treated With Oral Xeloda (Capecitabine).
NCT01136005	PHASE3	COMPLETED	Bepanthen Versus Cetomacrogol in Epidermal Growth Factor Receptor Inhibitors (EGFRI)
NCT01318889	PHASE2	UNKNOWN	Dexpanthenol Mouthwash to Treat Oral Mucositis
NCT04219358	PHASE1	TERMINATED	Topical Application of Imiquimod Gel at Different Concentrations in Actinic Cheilitis
NCT07395674	Not specified	NOT_YET_RECRUITING	Subcutaneous Dexpanthenol Administration and Wound Epithelialization
NCT07002632	Not specified	COMPLETED	Using Dexpanthenol Cream to Prevent Lip Corner Cracks in Children After Tonsil/Adenoid Surgery

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).